Akili, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported sales was USD 0.749 million compared to USD 0.111 million a year ago. Net loss was USD 11.15 million compared to USD 16.82 million a year ago.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4347 USD | +0.16% |
|
+2.19% | -10.76% |
18/06 | Akili's EndeavorOTC Gets FDA Clearance For ADHD Treatment | MT |
18/06 | Akili Gets FDA Clearance for ADHD Video Game Over-the-Counter Treatment | DJ |
1st Jan change | Capi. | |
---|---|---|
-10.76% | 34.17M | |
+4.85% | 216B | |
+9.86% | 190B | |
+31.11% | 152B | |
+34.08% | 113B | |
+1.90% | 64.04B | |
+19.45% | 54.34B | |
+1.63% | 49.21B | |
-3.12% | 39.41B | |
+1.93% | 35.99B |
- Stock Market
- Equities
- AKLI Stock
- News Akili, Inc.
- Akili, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023